Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine
Authors:
- Christian LaurentCLChristian Laurent
- Charles KouanfackCKCharles Kouanfack
- Sinata Koulla-ShiroSKSinata Koulla-Shiro
- Maguy NjoumeMNMaguy Njoume
- Yvette Mawamba NkeneYNYvette Mawamba Nkene
- Laura CiaffiLCLaura Ciaffi
- Charlotte BruletCBCharlotte Brulet
- Gilles PeytavinGPGilles Peytavin
- Laurence VergneLVLaurence Vergne
- Alexandra CalmyACAlexandra Calmy
- Eitel Mpoudi-NgoléEMEitel Mpoudi-Ngolé
- Eric DelaporteEDEric Delaporte
- 30 March 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (6) , 768-771
Abstract
We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high.Keywords
This publication has 20 references indexed in Scilit:
- Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and PrognosisClinical Infectious Diseases, 2005
- HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimenAIDS, 2005
- Ensuring the safety of HIV/AIDS generics.The Lancet, 2005
- A Combined-Formulation Tablet of Lamivudine/Nevirapine/Stavudine: Bioequivalence Compared With Concurrent Administration of Lamivudine, Nevirapine, and Stavudine in Healthy Indian SubjectsThe Journal of Clinical Pharmacology, 2005
- Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAARTJAMA, 2005
- Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialThe Lancet, 2004
- Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South AfricaAIDS, 2004
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and LamivudineAnnals of Internal Medicine, 2000